BrainMap

Mrs. Cristina Elena Dinu Pirvu

PhD

PROFESSOR - UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Researcher | Teaching staff | PhD supervisor

Web of Science ResearcherID: AAM-4265-2020

Curriculum Vitae (12/05/2024)

Expertise & keywords

Development of anticancer nanoparticulate systems based on novel metal complexes Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-5143 2020 - 2022

Role in this project:

Coordinating institution: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Project partners: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website: https://www.virology.ro/ro/cercetare/proiecte/proiect-ped-383-2020

Abstract:

A new generation of efficient metal-based drugs needs to be developed in order to overcome the biological, biopharmaceutical and biomedical drawbacks of standard chemotherapy. Use of metallo-drugs in cancer treatment has been hampered by an indaquate pharmacokinetic profile that limited the access to the biological target. This has led to the development of novel technologies based on nanostructured materials, acting as vectors for metallodrug delivery or simply as protectors of active species of the complexes for amplifying their activities and reducing their degradation. The aim of the project is to develop and validate new liposomal systems for transport and delivery of 2 promising anticancer agents previously studied by our research group. Nanoparticulate drug carrier systems will improve the therapeutic effectiveness and safety profile of these novel anticancer agents. The efficiency of these nanoformulations will be evaluated in terms of stability, drug entrapment efficiency, release behaviour, cell uptake, cytotoxicity, farmacotoxicology and pharmacokinetics. The project specific objectives are: 1) Development of liposomal systems validated at the laboratory level with novel anticancer agents; 2) Estimation the in vitro biological activity of the liposomal systems on various cell lines, including drug resistant cell lines, identifying biomarkers involved in modulating their biological activity; 3) Estimating the pharmaco-toxicological and pharmacokinetic profile of liposomal systems. Nanoparticles provide an enhanced bioavailability, in vivo stability, intestinal permeability, solubility, sustained and targeted delivery, therapeutic effectiveness of the anticancer drugs. The proposed project is a complex, interdisciplinary study related to biomedical international research, that aims to intends to transform modern methods, worldwide used in pharmacological, immunological and molecular biology studies, in instruments used for the translation to oncology.

OPTIMIZATION OF THE MODERN TECHNOLOGY FOR PROCESSING BREWING SPENT YEAST AND OBTAINING OF DERIVED PRODUCTS Call name: P 2 - SP 2.1 - Transfer de cunoaștere la agentul economic „Bridge Grant”
PN-III-P2-2.1-BG-2016-0308 2016 - 2018

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA

Project partners: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO); INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE - INCDTP BUCURESTI (RO); UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); PHARMACORP INNOVATION S.R.L. (RO); UNIVERSITATEA POLITEHNICA DIN BUCURESTI (RO); AGSIRA SRL (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://www.usamv.ro/dgpcsa-cdi/optimizarea-tehnologiei-moderne-de-procesare-drojdiei-uzate-de-bere-si-de-obtinere-produselor-derivate-biodryyeast/

Abstract:

The consortium consists of five research organizations that aim to obtain new products through optimization and validation of technologies, as well as to provide recommendation for the modernization of the existing production lines. The main objective of the industrial producer AGSIRA is to provide at least one new product to existing customers.

The research organizations will tackle together with AGSIRA the following issues established based on the needs identified at the industrial producer:

-design of a new production line to produce brewing yeast as feed through a new biotechnological process;

-obtaining a new product, having superior quality in comparison with the existing product in terms of composition, by optimizing the mixture between the yeast produced by the new technology with current processed spent brewing yeast;

-obtaining active brewing yeast (by freeze-drying and atomization);

-obtaining of derived products based on brewing yeast.

DESIGN, EVALUATION AND MODELING OF DRUG RELEASE MECHANISM FOR NOVEL TOPICAL MULTIPARTICULATE DELIVERY SYSTEMS Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2016-0813 2017 - 2018

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE - INCDTP BUCURESTI (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: https://umfcd.ro/cercetare-si-dezvoltare/proiecte/proiecte-nationale/proectarea-evaluarea-si-modelarea-mecanismului-de-eliberare-a-medicamentului-pentru-noi-sisteme-multiparticulate-de-cedare-topica/

Abstract:

TOPMULTINOV project is a new and modern concept for the development of smart biomaterial supports usable in burned skin repair. Efficient regeneration of burned skin is still a clinical challenge, obtaining of an adequate drug release support being a top approach in the field of biomaterials. The general objective of this project consists of the design, evaluation and modeling of an anti-inflammatory drug release mechanism from topical multiparticulate systems that will ensure a controlled release for burns healing. As a novelty element of the project, ensuring a proper anti-inflammatory drug delivery from spongious collagen-based supports using different techniques that allow a gradual degradation of collagen support and a slow release of drug is mentioned. The vehicle formulation in the drug delivery sciences is a critical quality attribute which needs special attention for tailor made design to rationalize the system development. Thus, the project presents a new approach concerning the preparation of release supports like collagen-based spongious matrices with an anti-inflammatory drug incorporated in free form, in free and encapsulated form, and in encapsulated form respectively, to model and control its release rate. The results generated by the preparation, physico-chemical and morphological characterization as well as the in vitro studies of drug release and testing of the designed topical systems on animal model will be disseminated at conferences, in specialty articles, and by patent application. The pluridisciplinarity and complementarity of both teams provide high level of scientific/technical experiences to ensure a successful project achievement. TOPMULTINOV is perfectly integrated in the national and European strategies with respect to the impact on human health for improved health and life quality.

Composed drug-impregnated biomaterials for postoperative complications Call name:
69BM/2016 2016 - 2017

Role in this project: Key expert

Coordinating institution: INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE-I.N.C.D.T.P. BUCURESTI SUCURSALA BUCURESTI INSTITUTUL DE CERCETARE PIELARIE - INCALTAMINTE I.C.P.I.

Project partners: INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE-I.N.C.D.T.P. BUCURESTI SUCURSALA BUCURESTI INSTITUTUL DE CERCETARE PIELARIE - INCALTAMINTE I.C.P.I. (); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (); SPITALUL CLINIC DE URGENTA "SF.PANTELIMON" ()

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" ()

Project website:

Abstract:

Studies on soil-plant-food-man correlations to obtain a food supplement with an increased content in iron of herbal origin Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-1572 2014 - 2017

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); HOFIGAL EXPORT IMPORT SA (RO); AGROECO BIOTERRA SRL (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://saliferoveg.umf.ro/index.html

Abstract:

Iron deficiency anemia (IDA) is the most common form of anemia in the world and the most frequent form of anemia in pregnant women. It is estimated that IDA has a prevalence of 2% among adult men and 9–20% among adult women. The multiple negative effects of anemia on health and quality of life justify the interventions designed to prevent and control anemia and the most important such intervention is the use of iron-containing food supplements.

The core objective of this project is to develop an iron-containing food supplement, using iron in its natural form, as an extract from plants rich in this oligoelement and, for this purpose, at exploring the correlations between soil, plants and the developed food supplement, to ensure an optimal use in humans. There are very few food supplements of botanical origin containing iron on the Romanian market (most of those available use iron salts). There is only a food supplement of Chinese origin containing iron (10 mg/tablet) and folic acid, the iron being derived from an extract of the so-called “black fungi powder” (with no taxonomic identification of the fungi species) and one manufactured locally (in two slightly different formulas) but with very small amounts of iron (“Fier biologic”, containing much less than 1.0 mg of Fe per capsule).

For this purpose we would explore the correlation between soil iron and iron in plants, by analyzing iron contents in at least 10 plant species (for at least 2 parts of the plant species – root, stem, leaf, seeds) grown on various soils in Romania and using statistical methods of regression to verify the relationship between the two variables. Because – as shown in section 1.2. – iron bioavailability is most often affected by other components of the plants (especially phytates, polyphenols and flavonoids), we will also investigate the influence of the soils on the flavonoids and polyphenol contents (as phytates is most often found in significant amounts only in seeds and grains we will not investigate phytate).

Very little research has been concerned up to now to the correlation between plant iron uptake and polyphenols or flavonoid content in various plant parts. We will also explore the relationship between the ontogenetic stages of plants and their iron uptake. The studies published up to date have only looked into this relationship in a small number of species and have produced inconsistent results. These results will allow us to make a scientifically sound decision on what parts of the plants to use, at what maturity stage to be collected and grown on what soils, as starting material for an extract rich in iron. We will also investigate the best iron extraction method from herbal sources and the main variables affecting the efficiency of the extraction process of iron in its natural form from plants (the following variables will be investigated: extraction method, solvent, temperature, herbal product:solvent ratio, extraction time and particle size) and the possibility of obtaining and characterizing a standardized extract (to be used as a raw material for a finished product). Finally, we will formulate and develop an iron-containing food supplement of herbal origin at the prototype stage.

The project will create research synergies through the collaboration of three partners: the University of Medicine and Pharmacy “Carol Davila” Bucharest (with a multidisciplinary team comprising experts in pharmaceutical botany, phytochemistry, analytical chemistry, physical chemistry, pharmaceutical chemistry, pharmacology, pharmaceutical technology) SC Hofigal Export Import, one of the most important manufacturers of food supplements of herbal origin on the Romanian market and SC Agroeco Bioterra SRL, a company specialized in ecologically cultivating medicinal herbal species, being independently certified in this sense.

RESEARCH AND FORMULATION OF A NEW CLASS OF SYNERGIC ANALGESIC - ANTIINFLAMMATORY DRUG COMBINATIONS WITH IMPROVED BIOAVAILABILTY, EFFICACY AND SAFETY PROFILE Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-2071 2014 - 2017

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); Spitalul Universitar de Urgenta Militar Central "Dr.Carol Davila" (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE CRAIOVA (RO); UNIVERSITATEA BUCURESTI (RO); POLIPHARMA INDUSTRIES S.R.L. (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://www.algosyn.org

Abstract:

The project aims a “faster medicine” (an European priority), an unitary, optimal, complete approach, from pharmacological design to clinical trial and industrial development of synergic combinations of an analgesic (acetaminophen), an analgesic - anti-inflammatory (acetylsalicylic acid), caffeine and chlorphenamine or other antihistaminic, exhibiting analgesic, anti-inflammatory and decongestive action, formulated as tablets, enterosoluble dragees, capsules.

The technical problem proposed to be solved in the project is that of obtaining the anti-inflammatory, analgesic and decongestant effects in pain related to inflammatory processes, particularly those in migraine, lumbar discopathy and/or lumbago, when smaller than regular quantities of active substances are administered, with relative higher efficiency than the substances administered individually and with reduced side effects and higher patient tolerance.

Additional to superior effects in comparison with the individual components, the essential , original feature of the new products will be that of obtaining comparable effects as other similar drug combinations but at two-three times lower doses, which implies also a significant reduction of adverse events. Particularly, the administration of acetylsalicylic acid as a nanostructured formulation diminishes high local concentrations of dissolved drug in the gastro-intestinal tract which is expected to minimize gastro-intestinal irritancy.

Research looks for a class of new combinations having as leading drug a synergic combination between chlorphenamine, caffeine, acetaminophen and acetylsalycilic acid, existing in the weight ratios of 1/10/30/40) patented by the project director and finalized as a drug, Algopirin, authorized by National Medicines Agency and produced by the industrial partner of the project. The most remarkable result was a strong anti-migraine effect.

The originality of the project lies also in the methodology and phenomenological modelling. The methodological approach will be based on powerful design of experiments, mainly cross-over, mathematical modelling and statistical tools. This could offer a chance of understanding the variability mechanisms and time-course of the processes which will allow to obtain statistical and clinical significant results, starting from a minimum number of experimental and clinical trials.

Pharmaco/ Toxico/ Kinetics and Dynamics modelling would have as result the elaboration of general and personalized therapeutic schedules for new drugs, prevention of non- responsiveness appearance following an inappropriate pharmacokinetics. Design, elaboration and characterization of classical and/or supramolecular organic core-shell nano-silica reservoirs, for release of active components, will be the contribution in the project of the colloid chemistry partner team and the industrial partner of the project. Nanostructured formulations will provide improved dissolution rate of active components that would result in enhanced bioavailability allowing a smaller dose to achieve same in vivo blood levels.

The most significant feature of the project is the aim of finalizing the researches with new, in the same time more safe and efficient drugs.

INNOVATIVE THERAPEUTIC PRODUCTS WITH PROPHILACTIC AND CURATIVE ACTION FOR ZOO-VETERINARY SECTOR Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-0953 2014 - 2017

Role in this project: Partner team leader

Coordinating institution: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA

Project partners: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO); UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); ASOCIATIA CENTRU DE CERCETARE STIINTIFICA IN DOMENIUL BIOCHIMIEI APLICATE SI BIOTEHNOLOGIEI (BIOTEHNOL) (RO); BIOING S.A. (RO); HOFIGAL EXPORT IMPORT SA (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://sanovet.fifim.ro/

Abstract:

Title: „INNOVATIVE THERAPEUTIC PRODUCTS WITH PROPHILACTIC AND CURATIVE ACTION FOR ZOO-VETERINARY SECTOR”

Acronym: SANOVET

Program: PARTNERSHIPS

Subprogram: “ Applied Collaborative Research Projects”

Domain 5 - Agriculture, food safety and security

Research thematic: 5.1.4. Methods, techniques and technologies for growth and diversification of animal production and fisheries, veterinary protection insurance Animal health is a concern for all European citizens. This concern stems from the public health, food safety and food security aspects, which are related to animal health but also to economic costs that animal disease outbreaks can trigger. This project uses a very common and a high economical and ecologically impact disease model like inflammation, as a paradigm for a conceptual and practical approach aimed to capitalize inexpensive and available resources.

The project goal is to improve the level of veterinary protection by developing a semi - solid phytoproduct from indigenous flora with topical application.

Main objectives that will ensure the achievement of project aim are:

1. Obtaining crops to exploit the curative potential of Anthriscus sp.;

2. Obtaining the phytocomplex;

3. Evaluating extracts pharmacological viability;

4. Obtaining an innovative phytoproduct .

The results of this research project will be materialized through:

1. Development and characterization of a herbal extract enriched in active ingredients with a complex chemical structure, non-toxic, based on original recipe obtained from association of fractionated extract with volatile oil from Anethum sp properly processed,

2. Highlighting the biologic activity, which plays a role in sustaining and accelerating the healing process by in vivo testing of herbal extract,

3. Creating a new topic semisolid phytoproduct.

The project addresses to a major agricultural problem in an interdisciplinary aggregate approach in order to achieve high yields results with a low economical input and a great environmental safety.

Development of a herbal medicinal product with topical administration in allergic dermatitides Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-1953 2014 - 2017

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); HOFIGAL EXPORT IMPORT SA (RO); AGROECO BIOTERRA SRL (RO); UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://www.umfcaroldavila.ro/index.php/activitatea-stiintifica/programe-pnii/1176-dezvoltarea-unui-medicament-pe-baza-de-plante-cu-administrare-topica-in-dermatoze-alergice

Abstract:

Immunological dysfunctions with cutaneous manifestations, such as urticaria, contact dermatitis or atopical dermatitis are social problems affecting a considerable part of the population, especially in the developed countries. Adverse effects accompanying the topical treatment with the current medicinal products limit their use for all the patients. Through this project we aim at developing and obtaining by technologies an original product – a herbal medicinal product of topical use intended in the treatment of cutaneous conditions mediated immunologically, thus contributing to the increase of the quality of life of the affected patients. The product will ensure the treatment of pathologies affecting a high number of patients, both at the national and international level. Although the herbal material initially used to define the standardized extract will be derived from ecological cultures (the risk of contamination with chemical allergenes being non-existent), the final objective is its production through biotechnologies, so as to allow the obtaining of the active raw material in appropriate amounts, of acceptable purity and independently of the seasonal cultures.

For this purpose the content in biocompounds with antiallergic potential activity from 10 herbal species (Morus alba L., Amaranthus caudatus L., Sambucus nigra L., Rubus idaeus L., Momordica charantia Descourt., Plantago lanceolata L., Ribes nigrum L., Rubia tinctorum L., Cynara scolymus L., Achillea millefolium L.) will be explored, as well as their correlation with the antiallergic activity (also at immunological level), for their later purification and obtaining of the pharmaceutical active extract. This will ensure the identification of the species, extract and fraction with the highest efficacy (in the indication of interest – allergies which may be treated topically) and safety proven in preclinical models. A biotechnology (cultures of plant tissues) of obtaining the active component of a topical medicinal product with antiallergic activity, identified based on the pharmacological and biochemical data and the variables affecting qualitatively and quantitatively the characteristics of the biomass obtained in the tissue culture, including the composition in active principles of interest, will be assessed. This will allow optimisation of the biotechnological process of obtaining the standardized extract that will constitute the active substance of the medicinal product for topical use.

Until now, no scientific study has reported the investigation of the antiallergic activity at topical level of purified extracts from these species or has examined the correlation of such an activity with the imunological effects and the classes of phytochemicals responsible for this activity. On the Romanian market several products of herbal nature are marketed in this therapeutical area, but they have not been developed scientifically and are not authorized as medicinal products (being not listed in the official Register drawn out by the National Agency for Medicines and Medical Devices), but (probably) as medical devices, which means that they act mainly through a mechanical effect, of barrier or by ensuring hydration, but not by an anti-inflammatory/antiallergic activity proper, of a pharmacological nature.

The project will be realized by the collaboration of three partners: The University of Medicine and Pharmacy “Carol Davila” Bucharest (with a multidisciplinary team of experts in pharmaceutical botany, phytochemistry, pharmacology, biochemistry, pharmaceutical chemistry, physical chemistry and pharmaceutical technology), the University of Agronomical Sciences and Veterinary Medicine Bucharest (with a team of experts in the field of biotechnology), SC Hofigal Export Import (one of the most important producers of medicines of herbal origin on the Romanian market) and SC Agroeco Biottera SRL (a company specialized in the ecological cultivation of herbal medicinal species).

Design and development of transport and delivery systems for new ruthenium compunds with antitumor activity Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1454 2012 - 2016

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI (RO); UNIVERSITATEA BUCURESTI (RO); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); PHARMA SERV INTERNATIONAL SRL (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://cercetare-umf.ro/uploads_ro/592/Pagina_web_136_2012-actualizata_2016.pdf

Abstract:

The proposed cooperative study is a complex interdisciplinary approach aimed at developing pharmaceutical product models with significant antitumor action and minimal side effects. During the project, three pharmaceutical systems that include some ruthenium complexes will be studied regarding solubility, capacity to transport and deliver the active substance at the final site of action, the antitumor activity and the side effects. The final scope of the project is to select the system (or systems) who best meet the requirements regarding bioavailability and pharmaco-toxicological properties for a possible inclusion in the clinical trials of the studied ruthenium complexes.

The proposed project has least three main goals. First, we want to develop pharmaceutical systems for improve the solubility of some ruthenium compounds in order to achieve a better pharmacokinetic profile for these compounds. Second, we intend to evaluate the antitumor activity of the developed systems using various cell lines from solid tumors and in vivo, comparing to cisplatin as reference substance. Third, we intend to evaluate the general toxicity of the developed systems, comparing to cisplatin. Additionally, we want to explore the possibility of development of these products as oral drugs and to establish what kind of cancer can be treated with these agents.

Studies concerning the obtaining of transdermal hormonal systems using the lyposomes as transport and drug controlled release vectors Call name:
61-024/2007 2007 - 2010

Role in this project: Project coordinator

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (); UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (); INSTITUTUL NATIONAL DE CERCETARE - DEZVOLTARE CHIMICO - FARMACEUTICA - I.C.C.F. BUCURESTI (); PHARMA SERV INTERNATIONAL SRL ()

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" ()

Project website:

Abstract:

Development of a QSAR bioinformatic sistem for modeling of antitumoral and antirheumatic therapeutic agents in individualized therapies Call name:
61-037/2007 2007 - 2010

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (); INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE IN DOMENIUL PATOLOGIEI SI STIINTELOR BIOMEDICALE "VICTOR BABES" (); UNIVERSITATEA BUCURESTI (); TERRASIGNA SRL ()

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" ()

Project website: http://bioinfoqsar.asrc.ro/

Abstract:

Abordări interdisciplinare pentru creșterea vizibilității și impactului activității de cercetare a UMFCD Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2024
CNFIS-FDI-2024-F-0570 2024 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

DEzvoltarea capacității instituționale a UMFCD pentru cercetare și inovare transdisciplinară în domeniul terapiilor inovative Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2023
CNFIS-FDI-2023-F-0708 2023 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

Atingerea scopului proiectului, afiliat misiunii instituționale de cercetare avansată care vizează obținerea de rezultate înalt performante, este posibilă prin realizarea următoarelor obiective:

O1. Dezvoltarea performanței infrastructurii de susținere a activității de cercetare în scopul creșterii capacităților CDI la nivel instituțional prin (i) renovarea și extinderea spațiilor dedicate activităților de cercetare în domeniul terapiilor inovative, (ii) extinderea bazei materiale (mentenanță și upgrade module existente, noi elemente de infrastructură achiziționate prin cofinanțare), (iii) facilitarea accesului la baze de date și alte instrumente digitale suport pentru activitatea de cercetare, dar și prin (iv) asigurarea sustenabilității proiectelor de cercetare ale universității prin achiziția de materiale consumabile/reactivi.

O2. Creșterea performanței resursei umane implicate în activități CDI orientate în sfera terapiilor inovative. Astfel, se susține strategia instituțională de dezvoltare a resursei umane prin (i) susținerea participării personalului implicat în activitatea de cercetare la stagii de instruire, dar și (ii) stimularea implicării tinerilor în activitățile CDI prin organizarea unor sesiuni de instruire interdisciplinare din sfera terapiilor inovative dedicate atât cercetători aflați la început de carieră, cât și studenților de la toate ciclurile de studiu.

O3. Optimizarea suportului administrativ în susținerea implementării proiectelor de cercetare aflate în derulare, prin definirea sau actualizarea unor (i) fluxuri de lucru și (ii) proceduri în vederea optimizării mecanismelor instituționale de susținere a cercetării și pentru asigurarea bunei desfășurări a proiectelor de cercetare.

O4. Creșterea vizibilității UMFCD bazată pe creșterea impactului diseminării rezultatelor activităților de cercetare prin sprijinirea (i) publicării acestora în reviste cotate ISI în regim open access, dar și (ii) diseminării lor la manifestări științifice.

Dezvoltarea capacității instituționale a UMFCD pentru susținerea activităților CDI în direcția terapiilor personalizate Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2022
CNFIS-FDI-2022-0253 2022 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

Atingerea scopului proiectului se poate realiza prin îmbunătățirea performanțelor infrastructurii de cercetare deja existente și dezvoltarea continuă a resursei umane implicate în activitățile CDI pentru a putea crește nivelul de interdisciplinaritate și complexitatea rezultatelor obținute, vizibilitatea UMFCD pe plan internațional și atingerea dezideratului de pol de referință în direcția terapiilor personalizate. În acest sens obiectivele proiectului sunt:

O1. Dezvoltarea și optimizarea performanței infrastructurii de cercetare a UMFCD în domeniul terapiilor personalizate în vederea coagulării unor noi nuclee de cercetare înalt performante, prin: (i) extinderea bazei materiale (mentenanță module existente, noi module și echipamente achiziționate prin cofinanțare, amenajare spații laboratoare) și (ii) asigurarea sustenabilității proiectelor de cercetare în curs de derulare prin achiziția de materiale consumabile/reactivi).

O2. Creșterea performanțelor echipelor interdisciplinare de cercetare din UMFCD în direcția terapiilor personalizate, prin (i) susținerea participării resursei umane la manifestări ştiinţifice/stagii de instruire de profil, (ii) facilitarea accesului și stimularea implicării studenților/masteranzilor/doctoranzilor în echipele interdisciplinare CDI.

O3.Asigurarea suportului pentru creșterea vizibilității și valorificarea rezultatelor cercetărilor prin (i) susținerea publicării în reviste cotate ISI în regim open access, (ii) promovare instituțională.

Consolidarea la nivel Institutional a competetențelor CDI ale colectivelor pluridisciplinare implicate în dezvoltarea direcțiilor prioritare de cercetare ale UMFCD Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2021
CNFIS-FDI-2021-0300 2021 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

Atingerea scopului proiectului, afiliat misiunii instituționale de cercetare avansată care vizează obținerea de rezultate înalt performante și a unei poziții strategice în spatiul european este posibilă prin realizarea următoarelor obiective:

O1.Susținerea și dezvoltarea resursei umane implicate în colectivele pluridisciplinare CDI prin consolidarea competențețor în ariile strategice de cercetare asumate la nivel instituțional. Acest obiectiv va fi realizat prin (i)susținerea participării resursei umane la manifestări ştiinţifice, (ii)stimularea implicării tinerilor cercetători în activitățile CDI, (iii)eficientizarea suportului administrativ dedicat activităților CDI

O2.Optimizarea performanței infrastructurii de cercetare existente. Acest obiectiv va fi realizat prin (i)asigurarea mentenanței și îmbunătățirea funcționării echipamentelor existente, (ii)materiale consumabile necesare activităților de cercetare, precum și pentru a celor aferente realizării lucrărilor finale pentru toate ciclurile de studiu, (iii)optimizarea funcționării biobazei din cadrul UMFCD pentru susținerea activităților de cercetare care implică lucrul cu animalul de laborator vertebrat, viu în conformitate cu normele legislative în vigoare (legea 43/2014)

O3.Asigurarea suportului pentru creșterea vizibilității prin valorificarea rezultatelor cercetărilor prin (i)susținerea publicării în reviste cotate ISI, (ii)susținerea activităților de transfer tehnologic și inovare, (iii)promovare instituțională

Susținerea cercetării de excelență în domeniul Sănătate prin optimizarea modelelor experimentale preclinice Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2020
CNFIS-FDI-2020-0604 2020 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

Atingerea scopului este posibilă prin asumarea următoarelor obiective:

O1. Stimularea activităților de cercetare interdisciplinară de excelență. Realizat prin (i) optimizarea modelelor experimentale preclinice (in silico, in vitro, in vivo) utilizate în domeniul Sănatate și asigurarea unei interfețe funcționale între cercetarea fundamentală și cea aplicativă; (ii) menținerea dialogului cu diferiți parteneri din mediul privat/public prin realizarea unor intâlniri de lucru pentru orientarea temelor de cercetare prioritare ale UMFCD către latura aplicativă și valorificarea oportunităților de transfer tehnologic.

O2. Optimizarea performanței infrastructurii de cercetare în scopul îmbunătățirii funcționării echipamentelor de cercetare existente.

O3. Asigurarea funcționării în bune condiții a biobazei din cadrul UMFCD pentru susținerea activităților de cercetare care implică lucrul cu animalul de laborator vertebrat, viu în conformitate cu normele legislative în vigoare (legea 43/2014).

O4. Asigurarea suportului pentru excelență în cercetare bazat pe creșterea impactului diseminării rezultatelor prin sprijinirea publicării de lucrări științifice în reviste de specialiate cotate/indexate ISI și participarea la manifestări științifice de profil.

Susținerea activității de cercetare de excelență în domeniul Sănătate a Universității de Medicină și Farmacie ”Carol Davila” din București Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2019
CNFIS-FDI-2019-0534 2019 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

Scopul propunerii de proiect este de a susține activitatea de cercetare de excelență în domeniul Sănătate a Universității de Medicină și Farmacie ”Carol Davila” din București (UMFCD) prin realizarea unei interfețe funcționale între cercetarea fundamentală, preclinică și clinică. Atingerea scopului este posibilă prin realizarea următoarelor obiective:

O1.Creșterea gradului de complexitate a cercetărilor interdisciplinare realizate în cadrul UMFCD prin creșterea performanței resursei umane implicate în Domeniul Sănătate. Acest obiectiv va fi realizat prin (i) creșterea gradului de deschidere al colectivelor de cercetare de excelență pentru abordarea integrată, inter- și transdisciplinară în domeniul Sănătate, (ii) susținerea unor nuclee de competență și excelență ale UMFCD în domeniul Sănătate, care să permită dezvoltarea de noi programe de masterat/doctorat.

O2.Asigurarea funcționării în bune condiții a infrastructurii de cercetare existente, prin asigurarea mentenanței și îmbunătățirea funcționării echipamentelor existente.

O3.Creșterea ratei de succes a propunerilor de proiecte de cercetare depuse în cadrul diferitelor programe de finanțare din fonduri publice/private.

O4.Asigurarea suportului pentru valorificarea rezultatelor cercetărilor de excelență prin (i) susținerea publicării în reviste cotate ISI și (ii) susținerea activităților de transfer tehnologic și inovare.

Perfecționarea unor echipe interdisciplinare de cercetare pentru optimizarea modelelor experimentale/funcționale în subdomeniul Știința medicamentului Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2018
CNFIS-FDI-2018-0507 2018 -

Role in this project: Project coordinator

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website:

Abstract:

Scopul propunerii de proiect este de a menține și dezvolta suportul adecvat derulării activităților de cercetare de excelență din subdomeniul Știința medicamentului în cadrul unor echipe interdisciplinare, punând accent pe optimizarea modelelor experimentale/funcționale aplicabile în domeniul medicamentului, în vederea publicării de lucrări în zona roșie/galbenă. Atingerea scopului este posibilă prin asumarea următoarelor obiective:

O1.Dezvoltarea oportunităților de cercetare și creșterea performanțelor echipelor interdisciplinare. Realizat prin optimizarea activității echipelor de cercetare interdisciplinară prin (i) armonizarea planului de lucru și a procedurilor din cadrul experimentului și (ii) gestionarea riscurilor prin identificarea și minimizarea punctelor slabe prin stabilirea nevoilor de instruire/specializare/perfecționare

O2.Creșterea performanței infrastructurii de cercetare, prin îmbunătățirea funcționării echipamentelor existente

O3.Creșterea ratei de succes a propunerilor de proiecte de cercetare depuse în cadrul diferitelor programe de finanțare din fonduri publice/private. Realizat prin identificarea de parteneri complementari din mediul academic/cercetare/industrie din sectorul public/privat, pentru realizarea unor protocoale de colaborare care să crească complexitatea cercetărilor

O4.Asigurarea suportului pentru excelență în cercetare bazat pe creșterea impactului diseminării rezultatelor prin publicare în reviste din zona roșie/galbenă sau brevetare

Call name: Premierea obtinerii atestatului de abilitare - Competitia 2015
PN-II-RU-ABIL-2015-2-0243 2015 -

Role in this project: Project coordinator

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website:

Abstract:

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator
List of research grants as partner team leader
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects